[
    [
        {
            "time": "2020-11-04",
            "original_text": "与拜恩泰科合作生变？复星医药：在推动两款新冠疫苗国内上市",
            "features": {
                "keywords": [
                    "拜恩泰科",
                    "复星医药",
                    "新冠疫苗",
                    "国内上市"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "与拜恩泰科合作生变？复星医药：在推动两款新冠疫苗国内上市",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-11-04",
            "original_text": "复星：新冠疫苗临床Ⅰ期进入数据分析阶段，临床Ⅱ期桥接试验积极筹备中",
            "features": {
                "keywords": [
                    "复星",
                    "新冠疫苗",
                    "临床Ⅰ期",
                    "数据分析",
                    "临床Ⅱ期",
                    "桥接试验"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星：新冠疫苗临床Ⅰ期进入数据分析阶段，临床Ⅱ期桥接试验积极筹备中",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-11-04",
            "original_text": "市场消息：复星医药计划不再继续进行与BioNTech SE合作的、目前已在中国开展测试的新冠疫苗临床测试，转而寻求该公司其他候选新冠疫苗在中国的许可",
            "features": {
                "keywords": [
                    "复星医药",
                    "BioNTech SE",
                    "新冠疫苗",
                    "临床测试",
                    "候选疫苗",
                    "中国市场"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "市场消息：复星医药计划不再继续进行与BioNTech SE合作的、目前已在中国开展测试的新冠疫苗临床测试，转而寻求该公司其他候选新冠疫苗在中国的许可",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-11-04",
            "original_text": "复星医药：与BioNTech SE合作的临床Ⅱ期桥接试验积极筹备中",
            "features": {
                "keywords": [
                    "复星医药",
                    "BioNTech SE",
                    "临床Ⅱ期",
                    "桥接试验"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：与BioNTech SE合作的临床Ⅱ期桥接试验积极筹备中",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-11-04",
            "original_text": "复星医药(02196.HK)拟为控股子公司复星医药产业不超1亿元融资提供担保",
            "features": {
                "keywords": [
                    "复星医药",
                    "控股子公司",
                    "融资",
                    "担保"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)拟为控股子公司复星医药产业不超1亿元融资提供担保",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-11-04",
            "original_text": "A股收盘综述：上证指数缩量小涨，中国人寿、君正集团领跌蚂蚁金服概念股",
            "features": {
                "keywords": [
                    "A股",
                    "上证指数",
                    "中国人寿",
                    "君正集团",
                    "蚂蚁金服"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "A股收盘综述：上证指数缩量小涨，中国人寿、君正集团领跌蚂蚁金服概念股",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-11-04",
            "original_text": "赣锋锂业、复星医药等港股获南向资金持股比例超20%",
            "features": {
                "keywords": [
                    "赣锋锂业",
                    "复星医药",
                    "港股",
                    "南向资金",
                    "持股比例"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "新能源"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "赣锋锂业、复星医药等港股获南向资金持股比例超20%",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]